A5078936217- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Global Cancer Incidence and Screening
- Hemoglobinopathies and Related Disorders
- Advancements in Semiconductor Devices and Circuit Design
- Iron Metabolism and Disorders
- Frailty in Older Adults
- CNS Lymphoma Diagnosis and Treatment
- Ethics in Clinical Research
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Smoking Behavior and Cessation
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Cancer therapeutics and mechanisms
- Nanowire Synthesis and Applications
- Testicular diseases and treatments
- Glioma Diagnosis and Treatment
University of Alabama at Birmingham
2023-2025
Indiana University School of Medicine
2021-2022
Indiana University
2022
University School
2022
Indiana University – Purdue University Indianapolis
2021-2022
Indiana University Health
2021-2022
The University of Texas Health Science Center at San Antonio
2017-2021
South Texas Veterans Health Care System
2019-2021
Audie L. Murphy Memorial VA Hospital
2018
Chimeric antigen receptor (CAR) T-cell therapy has greatly transformed the treatment and prognosis of B-cell hematological malignancies. As CAR continues to be more readily adopted indications increase, field's recognition emerging toxicities will continue grow. Among adverse events associated with therapy, cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity (ICANS) are most common toxicities, while thrombotic represent an under-reported, life-endangering...
Cancer is the leading cause of death for Hispanics in USA. Screening and prevention reduce cancer morbidity mortality.This study administered a cross-sectional web-based survey to self-identified Hispanic residents state Indiana assess their cancer-related knowledge, beliefs, behaviors, as well identify what factors might be associated with screening prevention. Chi-square Fisher's exact test were used compare associations logistic regression develop both univariate multivariate models.A...
Central nervous system (CNS) mucormycosis is insidious and difficult to diagnose. It progresses rapidly causes high mortality. Rare cases have been reported during ibrutinib use, which poor prognosis. Through this case, we share the experience of successful diagnosis treatment. We also emphasize importance focusing on high-risk groups, early prompt management.In a 52-year-old patient was diagnosed with chronic lymphocytic leukemia (CLL) for more than 5 years. He in remission after rituximab...
We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 who met inclusion criteria were predominantly male (97%) white (75%). Median age diagnosis for Black was 63 years vs 69 entire cohort (
Abstract Relapse remains a major cause of treatment failure following allogeneic stem cell transplantation (allo‐SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We retrospectively investigated low‐dose decitabine venetoclax (DEC/VEN) as post‐transplant maintenance in 26 older AML MDS. The cumulative incidence day 100 gIII‐IV graft versus host disease (GVHD) 1‐year moderate‐severe chronic GVHD was 5% 26%, respectively. One patient relapsed 14 m after...
The US veteran population has a high proportion of chronic lymphocytic leukemia (CLL) risk factors. Using the Veterans Health Administration (VHA) population, we conducted retrospective chart review 1205 CLL patients who initiated treatment with novel oral agent. For 1L ibrutinib, 33% (n = 107) discontinued therapy during study, which 64% due to adverse events (AEs). relapsed/refractory (R/R) 35% 262) therapy, 63% AEs. R/R venetoclax, 31% 27) 41% were idelalisib, 84% 41) 54% This real-world...
Acute myeloid leukemia (AML) results from the neoplastic transformation of a hematopoietic stem cell. While therapeutic progress has stagnated for several decades, recent in genomic classification AML paved way multiple new drug approvals. These long-awaited achievements represent paradigm shift approach to disease that largely been managed with conventional chemotherapy since 1970s. With evolution targeted therapies, novel agents continue be developed goal improve efficacy while minimizing...
Abstract Improving understanding of behaviors that increase or reduce cancer risk for different Hispanic groups is a public health priority; such knowledge sparse in new gateway immigration locations as Indiana. The aims this study were to: 1) describe beliefs and preventive/risk reduction (physical activity, tobacco, alcohol use) among adults; 2) examine differences preventive by country/territory birth, socioeconomic status, area residence (urban vs. rural); 3) determine predictors...
CNS involvement by CLL is a rare occurrence, usually happening in the context of transformation to more aggressive lymphoma what known as Richter’s transformation. We report patient with active who developed confusion and was found have West Nile encephalitis that initially mimicked CLL. The recovered supportive treatment later restarted ibrutinib therapy. This case illustrates importance maintaining broad differential among cancer patients new onset well questioning malignant infiltration...